home / stock / ruby / ruby news

RUBY News and Press, Rubius Therapeutics Inc. From 11/10/20

Stock Information
Company Name: Rubius Therapeutics Inc.
Stock Symbol: RUBY
Market: OTC
Website: rubiustx.com
Menu
RUBY RUBY Quote RUBY Short RUBY News RUBY Articles RUBY Message Board
Get RUBY Alerts

News, Short Squeeze, Breakout and More Instantly...
RUBY - Rubius Therapeutics to Participate in Jefferies Virtual London Healthcare Conference

CAMBRIDGE, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, today announced...
RUBY - Rubius Therapeutics EPS misses by $0.01

Rubius Therapeutics (RUBY): Q3 GAAP EPS of -$0.51 misses by $0.01.Cash, cash equivalents and investments of $207.9MPress Release For further details see: Rubius Therapeutics EPS misses by $0.01

RUBY - Rubius Therapeutics Reports Third Quarter 2020 Financial Results and Strong Execution Across the Pipeline

Completed Dosing of Fourth Cohort in RTX-240 Phase 1/2 Solid Tumor Clinical Trial Dosed First Patient in RTX-240 Phase 1 Relapsed/ Refractory Acute Myeloid Leukemia Clinical Trial Filed Investigational New Drug Application with U.S. Food and Dru...

RUBY - Rubius Therapeutics Presents Preclinical Data for Lead Red Cell Therapeutic(TM) Clinical Oncology Program, RTX-240, at the Society for Immunotherapy of Cancer's Annual Meeting

CAMBRIDGE, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, today announced...
RUBY - Rubius Therapeutics Announces Dosing of First Patient with Relapsed/Refractory Acute Myeloid Leukemia in the Ongoing Phase 1/2 Clinical Trial of RTX-240

CAMBRIDGE, Mass., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, today announced...

RUBY - Arcturus Progresses ARCT-810 Trial, And Other News: The Good, Bad And Ugly Of Biopharma

Arcturus Therapeutics progresses ARCT-810 trial, inks new ARCT-021 collaboration. ALX Oncology provides updates for ALX148 study in myelodysplastic syndrome. Rubius Therapeutics reports positive data for HPV-positive cancers therapy. For further details see: Arcturus Pro...

RUBY - Rubius Therapeutics to Announce Third Quarter 2020 Financial Results

CAMBRIDGE, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, today anno...
RUBY - Rubius Therapeutics' RTX-321 shows dual mechanism of action in HPV-positive cancers

Rubius Therapeutics (RUBY) presents new preclinical data supporting its lead artificial antigen-presenting cell (aAPC) program, RTX-321, for the potential treatment of human papillomavirus ((HPV)) 16-positive cancers at the Federation of Clinical Immunology Societies ((FOCIS)) Virtual Annual ...

RUBY - Rubius Therapeutics Presents Preclinical Data for RTX-321, a Red Cell Therapeutic(TM) Oncology Product Candidate for HPV-Positive Cancers, Demonstrating its Dual Mechanism of Action

CAMBRIDGE, Mass., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, today announced...

RUBY - Rubius Therapeutics Announces Preclinical Data Supporting its Lead Clinical Oncology Program, RTX-240, to be Presented at the Society for Immunotherapy of Cancer's Annual Meeting

CAMBRIDGE, Mass., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced that the company will present precli...
Previous 10 Next 10